Moderna
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Moderna announces EMA CHMP adopted positive opinion on updated Spikevax
Moderna announced EMA's CHMP adopted a positive opinion recommending marketing authorization for an updated COVID-19 mRNA vaccine Spikevax targeting SARS-CoV-2 variant JN.1, for individuals six months and older. The European Commission will decide on its use for the 2024-2025 autumn/winter season.
Moderna's New COVID-19 Vaccine Nears EU Approval
Moderna's COVID-19 mRNA vaccine for SARS-CoV-2 variant JN.1 received a positive opinion from EMA's CHMP, recommended for the 2024-2025 EU vaccination season, pending final authorization. This vaccine is part of Moderna's strategy to adapt to evolving variants, with approvals already in Japan, Taiwan, the UK, and the US.
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion
EMA's CHMP recommends marketing authorization for Moderna's updated COVID-19 mRNA vaccine targeting SARS-CoV-2 variant JN.1, for individuals 6 months and older, pending European Commission approval for the 2024-2025 vaccination season.
Moderna's mRNA-Based Mpox Vaccine Shows Promise in Monkey Trial
Moderna's mRNA-based mpox vaccine, mRNA-1769, shows promise in a monkey trial, outperforming older vaccines in reducing illness severity and lesion count, suggesting potential for better protection against mpox and related Orthopoxviruses.
Life Science Webinar Calendar for September 2024
Xtalks offers free webinars on biomarkers, cell and gene therapy, clinical trials, and more. Topics include new blood tests for amyloid pathology, CAR-T therapies, and AI in drug development. Register for free at http://www.xtalks.com.
U.S. Will Offer Free COVID Tests By Mail by Late September
U.S. to offer free COVID tests by mail starting late September, with each household able to order up to four tests. The program has distributed over 900 million tests since the pandemic began. The tests aim to help detect the virus and prevent its spread during the holiday season.
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
Moderna's updated COVID-19 vaccine targeting KP.2 variant of SARS-CoV-2 has been approved by the U.S. FDA for individuals 12 years and above, with EUA granted for those 6 months through 11 years. The vaccine aims to prevent COVID-19 and is expected to be available soon.
© Copyright 2024. All Rights Reserved by MedPath